Evidence map›Paper›PMID 35246165›Full record

ArticleHarm reduction journal2022

Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City.

Alex S Bennett, Joy Scheidell, Jeanette M Bowles, Maria Khan, Alexis Roth, Lee Hoff, Christina Marini, Luther Elliott

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Alex S BennettSchool of Global Public Health, New York University, New York, USA. asb19@nyu.edu.ORCID 0000-0001-6986-9925
Joy ScheidellCenter for Drug Use and HIV/HCV Research, New York University, New York, USA.
Jeanette M BowlesCentre for Drug Policy and Evaluation, Unity Health Toronto, 209 Victoria St, Toronto, ON, M5B 1T8, Canada.
Maria KhanCenter for Drug Use and HIV/HCV Research, New York University, New York, USA.
Alexis RothDornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
Lee HoffCenter for Opioid Epidemiology and Policy, Grossman School of Medicine, New York University, New York, USA.
Christina MariniSchool of Global Public Health, New York University, New York, USA.
Luther ElliottSchool of Global Public Health, New York University, New York, USA.
New York University · USDrexel University · USUnity Health Toronto

Funding

Overdose Risk Management and Compensation in the Era of NaloxoneR01DA046653 · NIDA · NEW YORK UNIVERSITY · PI BENNETT, ALEXANDER S, ELLIOTT, LUTHER · 2018 to 2022
$4.4M
NIDA NIH HHS R01 DA046653
6 · The paper itself

Abstract

backgroundDespite increased availability of take-home naloxone, many people who use opioids do so in unprotected contexts, with no other person who might administer naloxone present, increasing the likelihood that an overdose will result in death. Thus, there is a social nature to being "protected" from overdose mortality, which highlights the importance of identifying background factors that promote access to protective social networks among people who use opioids.

methodsWe used respondent-driven sampling to recruit adults residing in New York City who reported recent (past 3-day) nonmedical opioid use (n = 575). Participants completed a baseline assessment that included past 30-day measures of substance use, overdose experiences, and number of "protected" opioid use events, defined as involving naloxone and the presence of another person who could administer it, as well as measures of network characteristics and social support. We used modified Poisson regression with robust variance to estimate unadjusted and adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs).

results66% of participants had ever been trained to administer naloxone, 18% had used it in the past three months, and 32% had experienced a recent overdose (past 30 days). During recent opioid use events, 64% reported never having naloxone and a person to administer present. This was more common among those: aged ≥ 50 years (PR: 1.18 (CI 1.03, 1.34); who identified as non-Hispanic Black (PR: 1.27 (CI 1.05, 1.53); experienced higher levels of stigma consciousness (PR: 1.13 (CI 1.00, 1.28); and with small social networks (< 5 persons) (APR: 1.14 (CI 0.98, 1.31). Having a recent overdose experience was associated with severe opioid use disorder (PR: 2.45 (CI 1.49, 4.04), suicidality (PR: 1.72 (CI 1.19, 2.49), depression (PR: 1.54 (CI 1.20, 1.98) and positive urinalysis result for benzodiazepines (PR: 1.56 (CI 1.23, 1.96), but not with network size.

conclusionsResults show considerable gaps in naloxone protection among people who use opioids, with more vulnerable and historically disadvantaged subpopulations less likely to be protected. Larger social networks of people who use opioids may be an important resource to curtail overdose mortality, but more effort is needed to harness the protective aspects of social networks.

Indexed as

Drug OverdoseOpioid-Related DisordersAdultAnalgesics, OpioidHumansMiddle AgedNaloxoneNarcotic AntagonistsNew York CityPublic PolicySocial NetworkingSocial SupportAnalgesics, OpioidNaloxoneNarcotic AntagonistsNaloxone protectionNon-fatal overdoseOpioidsSocial networks

Identifiers

PMID35246165
PMCPMC8894821
OpenAlexW4220839183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.